NSM to become exclusive CRT distribution partner for emerging personal exoskeleton
By HME News Staff
Updated 9:33 AM CDT, Mon June 29, 2026
NASHVILLE, Tenn. – National Seating & Mobility (NSM) and Wandercraft have entered a commercial partnership to prepare for future access to Eve, Wandercraft’s self-balancing personal exoskeleton designed for home use. Eve is currently under regulatory review by the U.S. Food and Drug Administration (FDA), with an anticipated launch in summer 2026, pending clearance. “Robotics and physical AI are redefining what’s possible for people with complex mobility needs,” said Crispin Teufel, CEO of NSM. “Close collaboration with our clinical partners and clients uniquely positions us to support the adoption of this innovative technology. Through this partnership with Wandercraft, we can broaden access in both rehabilitation and home environments.” Following FDA clearance, NSM will become Wandercraft’s exclusive CRT distribution partner for Eve, using its national network of more than 180 locations to support evaluation, education, access and delivery to eligible individuals with spinal cord injuries and other severe mobility impairments. The companies say the agreement is designed to help ensure that clinicians, assistive technology professionals (ATPs), payers and clients are prepared to understand Eve’s role in extending upright mobility from rehabilitation settings into the home. NSM will also promote broader awareness and adoption of other Wandercraft technologies, including Atalante X, the self-balancing rehabilitation exoskeleton. Atalante X, Wandercraft’s flagship self-balancing exoskeleton, is used in more than 150 clinical and research settings worldwide.
Comments